HomeCompareJFLEX vs MRK

JFLEX vs MRK: Dividend Comparison 2026

JFLEX yields 4.79% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $3.4K in total portfolio value
10 years
JFLEX
JFLEX
● Live price
4.79%
Share price
$9.27
Annual div
$0.44
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.4K
Annual income
$650.56
Full JFLEX calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — JFLEX vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJFLEXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JFLEX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JFLEX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JFLEX
Annual income on $10K today (after 15% tax)
$406.99/yr
After 10yr DRIP, annual income (after tax)
$552.98/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $254.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JFLEX + MRK for your $10,000?

JFLEX: 50%MRK: 50%
100% MRK50/50100% JFLEX
Portfolio after 10yr
$29.1K
Annual income
$800.43/yr
Blended yield
2.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

JFLEX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JFLEX buys
0
MRK buys
0
No recent congressional trades found for JFLEX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJFLEXMRK
Forward yield4.79%3.25%
Annual dividend / share$0.44$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$27.4K$30.7K
Annual income after 10y$650.56$950.29
Total dividends collected$5.7K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JFLEX vs MRK ($10,000, DRIP)

YearJFLEX PortfolioJFLEX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,179$478.81$11,192$351.54$13.00MRK
2$12,462$500.24$12,524$392.70$62.00MRK
3$13,855$521.16$14,015$438.65$160.00MRK
4$15,366$541.53$15,682$489.96$316.00MRK
5$17,003$561.31$17,547$547.23$544.00MRK
6$18,774$580.47$19,632$611.16$858.00MRK
7$20,687$598.99$21,963$682.53$1.3KMRK
8$22,752$616.86$24,571$762.18$1.8KMRK
9$24,979$634.05$27,486$851.08$2.5KMRK
10$27,378$650.56$30,745$950.29$3.4KMRK

JFLEX vs MRK: Complete Analysis 2026

JFLEXStock

The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in bonds. Bonds include, but are not limited to, government notes and bonds, corporate bonds, commercial and residential mortgage-backed securities, asset-backed securities, credit risk transfer securities (“CRTs”), and money market instruments. It will invest at least 65% of its net assets in investment grade debt securities. The fund will limit its investment in high-yield/high-risk bonds (also known as "junk" bonds) to 35% or less of its net assets.

Full JFLEX Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this JFLEX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JFLEX vs SCHDJFLEX vs JEPIJFLEX vs OJFLEX vs KOJFLEX vs MAINJFLEX vs JNJJFLEX vs ABBVJFLEX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.